The μ-opioid receptor gene polymorphism 118A>G weakens the pharmacological action of buprenorphine.
Journal
International journal of clinical pharmacology and therapeutics
ISSN: 0946-1965
Titre abrégé: Int J Clin Pharmacol Ther
Pays: Germany
ID NLM: 9423309
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
accepted:
09
10
2020
pubmed:
2
9
2020
medline:
2
12
2020
entrez:
2
9
2020
Statut:
ppublish
Résumé
Opioids are commonly used analgesics for moderate to severe pain, but levels of drug effect vary among individuals. As for the mechanisms underlying these individual differences, there have been reports suggesting effects of polymorphisms in the gene encoding μ-opioid receptor ( Ten healthy adult men (5 with Nociceptive thresholds were significantly increased in the AA as compared to the GG group after buprenorphine administration (p = 0.025), while the DSST scores were significantly lower in the AA group (p < 0.001). The VAS scores for drowsiness (p < 0.001), malaise (p < 0.001), nausea (p < 0.001), and euphoria (p = 0.004) were higher in the AA than in the GG group. Levels of pharmacological actions of a μ-opioid receptor partial agonist vary in accordance with a polymorphism in the
Identifiants
pubmed: 32870152
pii: 187229
doi: 10.5414/CP203755
doi:
Substances chimiques
Analgesics
0
Analgesics, Opioid
0
OPRM1 protein, human
0
Receptors, Opioid, mu
0
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM